• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc. (Amendment)

    2/14/24 4:18:21 PM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRNS alert in real time by email
    SC 13G/A 1 marinus13ga4-02142024.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    (Rule 13d-102)
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO RULE 13d-2(b)
    (Amendment No. 4)1
     
    Marinus Pharmaceuticals, Inc.
    (Name of Issuer)
    Common Stock, $0.001 par value
    (Title of Class of Securities)
    56854Q101
    (CUSIP Number)
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
     ☒
    Rule 13d-1(b)
     
     ☐
    Rule 13d-1(c)
     
     ☐
    Rule 13d-1(d)
     
     

     

    1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

    CUSIP NO. 56854Q101
     
                                           
     
    1
     
    NAME OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    LION POINT CAPITAL, LP
     
     
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
     
     
     
     
    (b) ☐
     
     
     
     
     
     
     
    3
     
    SEC USE ONLY
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
     
     
     
     
     
     
     
    DELAWARE
     
    NUMBER OF
     
    5
     
    SOLE VOTING POWER
     
    SHARES
     
     
     
     
     
    BENEFICIALLY
     
     
     
     
    - 0 -
     
    OWNED BY
     
    6
     
    SHARED VOTING POWER
     
    EACH
     
     
     
     
     
    REPORTING
     
     
     
     
    2,134,337
     
    PERSON WITH
     
    7
     
    SOLE DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    - 0 -
     
     
     
    8
     
    SHARED DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    2,134,337
     
     
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    2,134,337
     
     
    10
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
     
     
     
     
     
     
     
     
     
     
     
     
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
     
     
     
     
     
     
     
    3.9%
     
     
    12
     
    TYPE OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    IA, PN
     
     




    CUSIP NO. 56854Q101
     
                                           
     
    1
     
    NAME OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    LION POINT HOLDINGS GP, LLC
     
     
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
     
     
     
     
    (b) ☐
     
     
     
     
     
     
     
    3
     
    SEC USE ONLY
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
     
     
     
     
     
     
     
    DELAWARE
     
    NUMBER OF
     
    5
     
    SOLE VOTING POWER
     
    SHARES
     
     
     
     
     
    BENEFICIALLY
     
     
     
     
    - 0 -
     
    OWNED BY
     
    6
     
    SHARED VOTING POWER
     
    EACH
     
     
     
     
     
    REPORTING
     
     
     
     
    2,134,337
     
    PERSON WITH
     
    7
     
    SOLE DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    - 0 -
     
     
     
    8
     
    SHARED DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    2,134,337
     
     
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    2,134,337
     
     
    10
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
     
     
     
     
     
     
     
     
     
     
     
     
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
     
     
     
     
     
     
     
    3.9%
     
     
    12
     
    TYPE OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    HC, OO
     
     



    CUSIP NO. 56854Q101
     
                                           
     
    1
     
    NAME OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    DIDRIC CEDERHOLM
     
     
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
     
     
     
     
    (b) ☐
     
     
     
     
     
     
     
    3
     
    SEC USE ONLY
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
     
     
     
     
     
     
     
    SWEDEN AND FRANCE
     
    NUMBER OF
     
    5
     
    SOLE VOTING POWER
     
    SHARES
     
     
     
     
     
    BENEFICIALLY
     
     
     
     
    - 0 -
     
    OWNED BY
     
    6
     
    SHARED VOTING POWER
     
    EACH
     
     
     
     
     
    REPORTING
     
     
     
     
    2,134,337
     
    PERSON WITH
     
    7
     
    SOLE DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    - 0 -
     
     
     
    8
     
    SHARED DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    2,134,337
     
     
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    2,134,337
     
     
    10
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
     
     
     
     
     
     
     
     
     
     
     
     
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
     
     
     
     
     
     
     
    3.9%
     
     
    12
     
    TYPE OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    HC, IN
     
     



    CUSIP NO. 56854Q101
    Item 1(a).
    Name of Issuer:
     
    Marinus Pharmaceuticals, Inc. (the “Issuer”).
    Item 1(b).
    Address of Issuer’s Principal Executive Offices:
     
    5 Radnor Corporate Center, Suite 500, 100 Matsonford Rd, Radnor, PA 19087
    Item 2(a).
    Name of Persons Filing:

    This Schedule 13G (“Schedule 13G”) is being jointly filed by, Lion Point Capital, LP, a Delaware limited partnership (“Lion Point Capital”), Lion Point Holdings GP, LLC, a Delaware limited liability company (“Lion Point Holdings”) and Didric Cederholm, a dual citizen of Sweden and France. Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”
    Lion Point Capital is the investment manager to its investment fund client. Lion Point Holdings is the general partner of Lion Point Capital. Mr. Cederholm is a Founding Partner and Chief Investment Officer of Lion Point Capital. Mr. Cederholm is also a Member and a Manager of Lion Point Holdings. By virtue of these relationships, each of Lion Point Capital, Lion Point Holdings, and Mr. Cederholm may be deemed to beneficially own the securities beneficially owned by its investment fund client.
    Item 2(b).
    Address of Principal Business Office or, if none, Residence:

    The principal business office of each of the Reporting Persons is 250 West 55th Street, 33rd Floor, New York New York 10019.
    Item 2(c).
    Citizenship:

    Each of Lion Point Capital and Lion Point Holdings is organized under the laws of the State of Delaware. Mr. Cederholm is a dual citizen of Sweden and France.
    Item 2(d).
    Title of Class of Securities:

    Common Stock, $0.001 par value (the “Common Stock”)
    Item 2(e).
    CUSIP Number:

    56854Q101
    Item 3.
    If this statement is filed pursuant to Section 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     
    / /
    Not Applicable
    (a)
    / /
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b)
    / /
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)
    / /
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)
    / /
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)
    /X/
    Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E).*
    (f)
    / /
    Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F).
    (g)
    /X/
    Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G).**
    (h)
    / /
    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)
    / /
    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3).
    (j)
    / /
    Non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J).
    (k)
    / /
    Group, in accordance with Section 240.13d-1(b)(1)(ii)(J).

     

    Item 4.
    Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer.

    (a)
    Amount beneficially owned:
    As of the close of business on December 31, 2023, the Reporting Persons may be deemed to have  beneficially owned 2,134,337 shares of Common Stock.

    (b)
    Percent of class:
    As of the close of business on December 31, 2023, each Reporting Person may be deemed to have  beneficially owned  3.9% (based upon 54,573,581 shares of Common Stock to be outstanding as of November 3, 2023 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023).
    (c)            Number of shares of Common Stock as to which each Reporting Person has:

    (i)
    Sole power to vote or to direct the vote:
    See Cover Pages Items 5-9.

     (ii)
    Shared power to vote or to direct the vote
    See Cover Pages Items 5-9.

     (iii)
    Sole power to dispose or to direct the disposition of
    See Cover Pages Items 5-9.

     (iv)
    Shared power to dispose or to direct the disposition of
    See Cover Pages Items 5-9.
    The filing of this Schedule 13G shall not be construed as an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any of the shares of Common Stock reported herein. Each of the Reporting Persons specifically disclaims beneficial ownership of the shares of Common Stock reported herein that are not directly owned by such Reporting Person.
    Item 5.
    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof each reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [x].
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    Lion Point Capital’s client, Lion Point Master, LP, has the right to receive dividends and the proceeds from the sale of securities.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Incorporated by reference from Item 2.
    Item 8.
    Identification and Classification of Members of the Group.

    See Exhibit 99.1 to the Schedule 13G filed with the Securities and Exchange Commission on February 14, 2020.


    CUSIP NO. 56854Q101

    Item 9.
    Notice of Dissolution of Group.

    Not Applicable.
    Item 10.
    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    CUSIP NO. 56854Q101
    SIGNATURES
    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information with respect to it or him set forth in this statement is true, complete and correct.
    Dated: February 14, 2024
     
     
     
     
    LION POINT CAPITAL, LP
     
     
     
    By:
    Lion Point Holdings GP, LLC,
    its General Partner
     
     
     
     
    By:
    /s/ Didric Cederholm
     
     
    Name:
    Didric Cederholm
     
     
    Title:
    Manager and Member

     
     
    LION POINT HOLDINGS GP, LLC
     
     
     
    By:
    /s/ Didric Cederholm
     
     
    Name:
    Didric Cederholm
     
     
    Title:
    Manager and Member

     
     
     
     
    /s/ Didric Cederholm
     
     
    DIDRIC CEDERHOLM

     
    Get the next $MRNS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRNS

    DatePrice TargetRatingAnalyst
    9/23/2024$6.00Perform → Outperform
    Oppenheimer
    8/14/2024Buy → Neutral
    Ladenburg Thalmann
    4/16/2024$20.00 → $2.00Outperform → Neutral
    Robert W. Baird
    4/15/2024$24.00 → $3.00Outperform → Sector Perform
    RBC Capital Mkts
    8/11/2023$14.00 → $9.00Outperform → Perform
    Oppenheimer
    1/20/2023$23.00Outperform
    RBC Capital Mkts
    12/20/2021$32.00 → $30.00Outperform
    SVB Leerink
    More analyst ratings

    $MRNS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

    Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company committed to improving the lives of patients with seizure disorders, today announced that they have entered into an agreement and plan of merger under which Immedica has agreed to acquire Marinus, by means of a tender offer and subsequent merger. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241230307666/en/ The acquisition complements and further strengthens Immedica's global rare disease business by adding ZTALMY® (ganaxalone) oral suspension, CV, a neuroactive steroid gamma-aminobuty

    12/30/24 7:00:00 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

    ZTALMY® (ganaxolone) Q3 2024 net product revenue of $8.5 million representing growth of 56% versus Q3 2023 Narrowing full year 2024 ZTALMY net product revenue guidance to $33 to $34 million Reported results from Phase 3 TrustTSC trial and commenced process to explore strategic alternatives Marinus continues to support the commercial growth of ZTALMY; further ganaxolone clinical development has been suspended Scheduled to meet with FDA Q4 2024 to discuss a potential path forward for IV ganaxolone in refractory status epilepticus Cost reduction plans implemented with cash runway expected into Q2 2025; cash and cash equivalents of $42.2 million as of September 30, 2024 Marin

    11/12/24 4:00:00 PM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

    Trial did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency (p=0.09); results showed numerically higher response rates for ganaxolone than placebo Ganaxolone was generally well-tolerated in TrustTSC with a safety profile consistent with previous clinical trials Cost reduction activities are underway Marinus has engaged Barclays as an advisor to assist with evaluating strategic alternatives Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Phase 3 TrustTSC trial evaluating oral ganaxolone for the treatment of seizures as

    10/24/24 8:00:00 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ezickson Elan returned $5,995 worth of shares to the company (10,900 units at $0.55), closing all direct ownership in the company (SEC Form 4)

    4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)

    2/11/25 9:19:58 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fischer Seth H. Z. returned $8,254 worth of shares to the company (15,007 units at $0.55), closing all direct ownership in the company (SEC Form 4)

    4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)

    2/11/25 9:19:21 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF MEDICAL OFFICER Hulihan Joseph returned $39,999 worth of shares to the company (72,725 units at $0.55), closing all direct ownership in the company (SEC Form 4)

    4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)

    2/11/25 9:18:26 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRNS
    SEC Filings

    View All

    SEC Form 15-12G filed by Marinus Pharmaceuticals Inc.

    15-12G - MARINUS PHARMACEUTICALS, INC. (0001267813) (Filer)

    2/21/25 8:00:27 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Marinus Pharmaceuticals Inc.

    SCHEDULE 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

    2/14/25 4:00:04 PM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Marinus Pharmaceuticals Inc.

    EFFECT - MARINUS PHARMACEUTICALS, INC. (0001267813) (Filer)

    2/14/25 12:15:08 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRNS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Marinus Pharmaceuticals upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Marinus Pharmaceuticals from Perform to Outperform and set a new price target of $6.00

    9/23/24 7:37:13 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Marinus Pharmaceuticals downgraded by Ladenburg Thalmann

    Ladenburg Thalmann downgraded Marinus Pharmaceuticals from Buy to Neutral

    8/14/24 7:42:32 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Marinus Pharmaceuticals downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Marinus Pharmaceuticals from Outperform to Neutral and set a new price target of $2.00 from $20.00 previously

    4/16/24 8:12:28 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRNS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN AND CEO Braunstein Scott bought $6,526 worth of shares (5,933 units at $1.10) and returned $167,530 worth of shares to the company (304,600 units at $0.55), closing all direct ownership in the company (SEC Form 4)

    4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)

    2/11/25 9:11:48 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

    SC 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

    11/15/24 10:35:20 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Marinus Pharmaceuticals Inc.

    SC 13G - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

    11/14/24 6:39:04 PM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

    SC 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

    11/14/24 3:04:48 PM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRNS
    Financials

    Live finance-specific insights

    View All

    Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

    ZTALMY® (ganaxolone) Q2 2024 net product revenue of $8.0 million representing strong growth of 87% versus Q2 2023 On track to achieve full year 2024 ZTALMY net product revenue guidance of between $33 and $35 million Completed enrollment in the Phase 3 TrustTSC trial of oral ganaxolone in tuberous sclerosis complex (TSC) with topline data expected in the first half of Q4 2024 Expanded ZTALMY global footprint with activation of managed access programs for MENA, Russia and Canada with upcoming commercial launches anticipated in Europe and China Succeeded in post-grant review challenge of Ovid Therapeutics' U.S. Patent 11,395,817 for IV ganaxolone in the treatment of status epilept

    8/13/24 7:00:00 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ligand Reports Second Quarter 2024 Financial Results

    Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

    8/6/24 4:01:00 PM ET
    $AGEN
    $AMGN
    $CASI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024

    Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will host a conference call at 8:30 a.m. E.T. on August 13, 2024, to provide a business update and discuss financial results. Tuesday, August 13, 8:30 a.m. E.T. Domestic: (877) 405-1242 International: (201) 389-0852 Webcast Registration: Click Here An archived version of the call will be available approximately two hours after the completion of the event on the Marinus website at ir.marinuspharma.com/e

    7/30/24 8:00:00 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRNS
    Leadership Updates

    Live Leadership Updates

    View All

    DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

    Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh

    1/22/24 8:23:00 AM ET
    $DMAC
    $MRNS
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.

    Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors. "Sarah is an accomplished healthcare executive with extensive global clinical development and corporate strategy experience," said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. "With a track record of successfully advancing programs in various therapeutic areas using diverse modalities, a deep understanding of orphan diseases and over a decade of experience as a hospitalist physician, her unique perspective will be invalu

    5/17/23 4:01:00 PM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors

    Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Marvin H. Johnson, Jr. to its Board of Directors. "With over 34 years of diverse commercial operations experience at Merck & Co., we are delighted that Marvin is joining the Marinus Board," said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. "His impressive background launching products across multiple therapeutic categories, including neurology and acute care, will be invaluable in supporting the continued commercial success of ZTALMY® and in preparing for a potential hospital

    4/18/23 7:01:00 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care